PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.
At 7.3 years’ median follow-up, cabazitaxel failed to improve clinical PFS (62.8% vs 67.2%), metastasis-free survival, or overall survival versus androgen deprivation therapy plus radiotherapy.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced the commercial launch of ELEVIDYS (delandistrogene moxeparvovec) in Japan by Chugai ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results